Cover Image
市場調查報告書

非何杰金氏淋巴瘤:開發中產品分析

Non-Hodgkin Lymphoma - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 192737
出版日期 內容資訊 英文 1065 Pages
訂單完成後即時交付
價格
Back to Top
非何杰金氏淋巴瘤:開發中產品分析 Non-Hodgkin Lymphoma - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 1065 Pages
簡介

非何杰金氏淋巴瘤(NHL,或僅稱「淋巴瘤」),是從人體免疫系統淋巴球發病的癌症之一。人體各處均有可能出現,癌細胞擴展速度也完全因人而異。主要的症狀有盜汗、間歇性發熱·發冷、發癢、頭部·腋下·鼠蹊部等淋巴節肥大化、體重減少、咳嗽·呼吸急促(胸腺和胸部淋巴節受侵襲)、氣管和其他呼吸道的壓迫感、腹痛·膨脹感、食慾不振、便秘、噁心·嘔吐·頭痛、集中力的欠缺、人格變化、癲癇(腦部受侵襲)等。主要的治療方法有外科手術和放射治療、化療等。

本報告提供全球各國治療非何杰金氏淋巴瘤所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

非何杰金氏淋巴瘤概要

治療藥的開發

  • 非何杰金氏淋巴瘤開發中產品:概要
  • 非何杰金氏淋巴瘤開發中產品:比較分析

各企業開發中的非何杰金氏淋巴瘤治療藥

大學/研究機關研究中的非何杰金氏淋巴瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 階段不明的產品

非何杰金氏淋巴瘤治療藥:開發中的產品一覽(各企業)

非何杰金氏淋巴瘤治療藥:研究中的產品一覽(各大學/研究機關)

非何杰金氏淋巴瘤開發治療藥的企業

非何杰金氏淋巴瘤:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

非何杰金氏淋巴瘤治療藥:開發中產品的最新趨勢

非何杰金氏淋巴瘤治療藥:暫停開發的產品

非何杰金氏淋巴瘤治療藥:中止開發的產品

非何杰金氏淋巴瘤相關產品的開發里程碑

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7970IDB

Summary

Global Markets Direct's, 'Non-Hodgkin Lymphoma - Pipeline Review, H1 2016', provides an overview of the Non-Hodgkin Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma
  • The report reviews pipeline therapeutics for Non-Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Non-Hodgkin Lymphoma therapeutics and enlists all their major and minor projects
  • The report assesses Non-Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Non-Hodgkin Lymphoma Overview
  • Therapeutics Development
  • Non-Hodgkin Lymphoma - Therapeutics under Development by Companies
  • Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes
  • Non-Hodgkin Lymphoma - Pipeline Products Glance
  • Non-Hodgkin Lymphoma - Products under Development by Companies
  • Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes
  • Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
  • Non-Hodgkin Lymphoma - Therapeutics Assessment
  • Drug Profiles
  • Non-Hodgkin Lymphoma - Recent Pipeline Updates
  • Non-Hodgkin Lymphoma - Dormant Projects
  • Non-Hodgkin Lymphoma - Discontinued Products
  • Non-Hodgkin Lymphoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Non-Hodgkin Lymphoma, H1 2016
  • Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Actelion Ltd, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH , H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corporation, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Arno Therapeutics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Atara Biotherapeutics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by BioAtla, LLC, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by BioLineRx, Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Bionovis SA, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Cell Medica Limited, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Cellectis S.A., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Celon Pharma Sp. z o.o., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by CerRx, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Clonz Biotech Private Limited, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Formula Pharmaceuticals, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Galderma S.A., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Genosco, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Genzyme Corporation, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by iDD biotech SAS, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by IGF Oncology, LLC., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Innate Pharma S.A., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Komipharm International Co., Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by miRagen Therapeutics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Mirna Therapeutics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Mundipharma International Ltd, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by NantKwest, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by OncoSec Medical Incorporated, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Onxeo SA, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Panacea Biotec Limited, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Pharma Mar, S.A., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Polyphor Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Sanofi, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Sareum Holdings Plc, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by SciTech Development, LLC , H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by SialoTec GmbH , H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Solasia Pharma K.K., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Soligenix, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Targazyme, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Limited, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Trillium Therapeutics Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics, Inc., H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016
  • Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects, H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..13), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..14), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..15), H1 2016
  • Non-Hodgkin Lymphoma - Dormant Projects (Contd..16), H1 2016
  • Non-Hodgkin Lymphoma - Discontinued Products, H1 2016
  • Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H1 2016
  • Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H1 2016
  • Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H1 2016
  • Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H1 2016

List of Figures

  • Number of Products under Development for Non-Hodgkin Lymphoma, H1 2016
  • Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top